Drug
Difluoromethylornithine
Difluoromethylornithine is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(20%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
2
40%
Ph phase_2
3
60%
Phase Distribution
2
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
3(60.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Completed(2)
Terminated(1)
Other(1)
Detailed Status
Completed2
Recruiting1
Suspended1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (40.0%)
Phase 23 (60.0%)
Trials by Status
completed240%
recruiting120%
suspended120%
withdrawn120%
Recent Activity
1 active trials
Showing 5 of 5
recruitingphase_2
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
NCT04696029
suspendedphase_1
Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)
NCT06219174
completedphase_1
DFMO in Children With Type 1 Diabetes
NCT02384889
completedphase_2
Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients
NCT00204789
withdrawnphase_2
Urinary Biomarker Study With Sulindac and Difluoromethylornithine
NCT01636128
Clinical Trials (5)
Showing 5 of 5 trials
NCT04696029Phase 2
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
NCT06219174Phase 1
Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)
NCT02384889Phase 1
DFMO in Children With Type 1 Diabetes
NCT00204789Phase 2
Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients
NCT01636128Phase 2
Urinary Biomarker Study With Sulindac and Difluoromethylornithine
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5